General Information of Drug (ID: DMYGITU)

Drug Name
CHDI-340246 Drug Info
Indication
Disease Entry ICD 11 Status REF
Huntington disease 8A01.10 Preclinical [1]
Cross-matching ID
TTD Drug ID
DMYGITU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GSK065 DMO87YS Pancreatitis DC31-DC34 Phase 1 [3]
Isoxazoles and isoxazoline derivative 2 DMKCYSD N. A. N. A. Patented [4]
Aryl pyrimidine derivative 7 DM8FAW3 N. A. N. A. Patented [4]
Isoxazoles and isoxazoline derivative 1 DMRML9B N. A. N. A. Patented [4]
Aryl pyrimidine derivative 2 DMU9Y4B N. A. N. A. Patented [4]
Cyclopropane 1-carboxylic acid derivative 6 DM0OMBW N. A. N. A. Patented [4]
PMID27172114-Compound-47 DMTIQYD N. A. N. A. Patented [4]
Isoxazoles and isoxazoline derivative 4 DMW3JZV N. A. N. A. Patented [4]
Cyclopropane 1-carboxylic acid derivative 2 DMSXB58 N. A. N. A. Patented [4]
Cyclopropane 1-carboxylic acid derivative 9 DMLH9AQ N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Kynurenine 3-hydroxylase (KMO) TTIY56R KMO_HUMAN Inhibitor [2]

References

1 Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
2 The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease. Exp Neurol. 2016 Aug;282:99-118.
3 Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Nat Commun. 2017 Jun 12;8:15827.
4 Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.